Regular administration of exogenous granulocyte colony-stimulating factor (filgrastim) clinically improves neutrophil counts and immune function and is the mainstay of therapy, although this may increase risk for myelofibrosis and acute myeloid leukemia in the long term. Over 90% of<unk>  responds to treatment with granulocyte colony-stimulating factor (filgrastim), which has significantly improved survival.
Severe congenital neutropenia
Autoimmune neutropenia
Bare lymphocyte syndrome
Diffuse infiltrative lymphocytosis syndrome
Adult-onset immunodeficiency syndrome
Refractory cytopenia of childhood
Leukocyte adhesion deficiency
Myelodysplastic syndrome